| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 23/12/2024 | 12:01 | Edgar (US Regulatory) | Form 8-K - Current report | NYSE:OGN | Organon and Co |
| 19/12/2024 | 13:30 | Business Wire | Organon To Present at the 43rd Annual J.P. Morgan Healthcare Conference | NYSE:OGN | Organon and Co |
| 16/12/2024 | 13:30 | Business Wire | FDA Approves VTAMA® (tapinarof) cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older | NYSE:OGN | Organon and Co |
| 05/11/2024 | 13:29 | Business Wire | Update on FDA Review of VTAMA® (tapinarof) Cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older | NYSE:OGN | Organon and Co |
| 01/11/2024 | 13:06 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NYSE:OGN | Organon and Co |
| 31/10/2024 | 13:40 | Business Wire | 米国FDAが、PROLIA/XGEVA（デノスマブ）のバイオシミラー候補HLX14の生物学的製剤承認申請（BLA）を受理 | NYSE:OGN | Organon and Co |
| 31/10/2024 | 13:39 | Business Wire | US-amerikanische FDA akzeptiert BLA für HLX14 – den Biosimilar-Kandidat zu PROLIA/XGEVA (Denosumab) | NYSE:OGN | Organon and Co |
| 31/10/2024 | 13:39 | Business Wire | 美國FDA接受PROLIA/XGEVA（地諾單抗）生物學名藥候選藥物HLX14的生物製品授權申請(BLA) | NYSE:OGN | Organon and Co |
| 31/10/2024 | 12:30 | Business Wire | Organon Reports Results for the Third Quarter Ended September 30, 2024 | NYSE:OGN | Organon and Co |
| 31/10/2024 | 05:02 | Business Wire | La FDA des États-Unis accepte la demande de licence de produits biologiques (BLA) pour HLX14, le candidat biosimilaire de PROLIA/XGEVA (denosumab) | NYSE:OGN | Organon and Co |
| 30/10/2024 | 11:00 | Business Wire | US FDA Accepts Biologics License Application (BLA) for HLX14, Biosimilar Candidate of PROLIA/XGEVA (denosumab) | NYSE:OGN | Organon and Co |
| 29/10/2024 | 17:22 | Business Wire | Organon vollzieht Übernahme von Dermavant einschließlich der innovativen dermatologischen Therapie VTAMA® (Tapinarof) Creme, 1 % | NYSE:OGN | Organon and Co |
| 29/10/2024 | 17:22 | Business Wire | オルガノン、ダーマバントの買収を完了し、画期的な皮膚科治療薬VTAMA®（タピナロフ）クリーム1％を取得 | NYSE:OGN | Organon and Co |
| 29/10/2024 | 17:22 | Business Wire | Organon conclut l'acquisition de Dermavant, qui propose notamment un traitement dermatologique innovant : la crème VTAMA® (tapinarof) 1 % | NYSE:OGN | Organon and Co |
| 28/10/2024 | 14:25 | Business Wire | Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1% | NYSE:OGN | Organon and Co |
| 09/10/2024 | 13:30 | Business Wire | Organon to Report Third Quarter 2024 Results and Host Conference Call on October 31, 2024 | NYSE:OGN | Organon and Co |
| 08/10/2024 | 14:01 | PR Newswire (Canada) | Organon Canada Promotes Geneviève Gauthier as Executive Director, Corporate Affairs and Community Engagement and Appoints Jeffrey Malawski as Executive Director, Women's Health and Established Brands | NYSE:OGN | Organon and Co |
| 08/10/2024 | 14:01 | PR Newswire (Canada) | Organon Canada promeut Geneviève Gauthier au poste de directrice exécutive, Affaires corporatives et Engagement communautaire, et nomme Jeffrey Malawski comme directeur exécutif, Santé des femmes et marques établies | NYSE:OGN | Organon and Co |
| 30/09/2024 | 21:26 | Business Wire | パージェタ（Perjeta®）（ペルツズマブ）バイオシミラー候補HLX11の第3相比較臨床試験で主要評価項目を達成 | NYSE:OGN | Organon and Co |
| 30/09/2024 | 18:17 | Business Wire | Primärer Endpunkt in Phase-3-Vergleichsstudie zu Perjeta® (Pertuzumab) Biosimilar-Kandidat HLX11 erreicht | NYSE:OGN | Organon and Co |
| 30/09/2024 | 17:59 | Business Wire | Critères principal atteint dans une étude clinique comparative de phase 3 sur le candidat biosimilaire HLX11 du Perjeta® (pertuzumab) | NYSE:OGN | Organon and Co |
| 30/09/2024 | 12:00 | Business Wire | Primary Endpoint Met in Phase 3 Comparative Clinical Study of Perjeta® (pertuzumab) Biosimilar Candidate HLX11 | NYSE:OGN | Organon and Co |
| 26/09/2024 | 15:50 | PR Newswire (Canada) | Organon Canada and the Alberta Women's Health Foundation unite to raise awareness and advocate for universal access to contraception in Canada | NYSE:OGN | Organon and Co |
| 26/09/2024 | 15:49 | PR Newswire (Canada) | Organon Canada et l'Alberta Women's Health Foundation s'unissent pour accroître la sensibilisation et prôner l'accès universel à la contraception au Canada | NYSE:OGN | Organon and Co |
| 19/09/2024 | 20:30 | Business Wire | オルガノンがDermavantを買収し、画期的な皮膚科治療薬VTAMA®（タピナロフ）クリーム1%を取得 | NYSE:OGN | Organon and Co |
| 19/09/2024 | 14:00 | Business Wire | Organon acquiert Dermavant et sa thérapie dermatologique innovante, la crème VTAMA® (tapinarof), 1 % | NYSE:OGN | Organon and Co |
| 19/09/2024 | 14:00 | Business Wire | Organon erwirbt Dermavant und dessen innovative dermatologische Behandlung VTAMA® (Tapinarof) Creme, 1 % | NYSE:OGN | Organon and Co |
| 18/09/2024 | 13:30 | GlobeNewswire Inc. | Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1% | NYSE:OGN | Organon and Co |
| 05/09/2024 | 22:32 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NYSE:OGN | Organon and Co |
| 21/08/2024 | 02:13 | Business Wire | オルガノンとリリーが片頭痛治療薬の商業化契約を拡大、11の新しい市場に参入 | NYSE:OGN | Organon and Co |